Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to $212,839.

  • InMed Pharmaceuticals' Depreciation & Amortization (CF) fell 2.52% to $53,202 in Q3 2025 from the same period last year, while for Sep 2025 it was $211,462, marking a year-over-year decrease of 3.59%. This contributed to the annual value of $212,839 for FY2025, which is 3.08% down from last year.
  • InMed Pharmaceuticals' Depreciation & Amortization (CF) amounted to $212,839 in FY2025, which was down 3.08% from $219,600 recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $219,600 in FY2024 and a low of $120,866 during FY2021.
  • In the last 3 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $212,839 in 2025 and averaged $211,563.
  • In the last 5 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) surged by 53.61% in 2022 and then fell by 3.08% in 2025.
  • Yearly analysis of 5 years shows InMed Pharmaceuticals' Depreciation & Amortization (CF) stood at $120,866 in 2021, then skyrocketed by 53.61% to $185,657 in 2022, then rose by 8.94% to $202,249 in 2023, then grew by 8.58% to $219,600 in 2024, then fell by 3.08% to $212,839 in 2025.